Literature DB >> 29553532

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators.

Sandra Claes1, Thomas D'huys1, Anneleen Van Hout1, Dominique Schols1, Tom Van Loy2.   

Abstract

G protein-coupled receptors (GPCRs) are of great importance to the pharmaceutical industry as they are involved in many human diseases and include well-validated targets for therapeutic intervention. Discovery of lead compounds, including small synthetic molecules, that specifically inhibit the receptor's function, is an important initial step in drug development and relies on sensitive, specific, and robust cell-based assays. Here, we describe a kinetic cellular assay with a fluorescent readout primarily designed to identify receptor-specific antagonists that inhibit the intracellular Ca2+ release evoked upon the activation of the CXC chemokine receptor 4 (CXCR4) by its endogenous ligand, the CXC chemokine ligand 12 (CXCL12). A key advantage of this method is that it also enables screening of compounds endowed with intrinsic agonistic properties (i.e., compounds eliciting an increase in intracellular Ca2+ concentration in the absence of CXCL12) or compounds modulating the receptor's function via interaction with allosteric binding sites (i.e., positive and negative allosteric modulators (PAMs and NAMs, respectively)). On the down side, autofluorescent compounds might interfere with the assay's readout, thereby hampering reliable data interpretation. Most likely this assay can be implemented, with minimal adaptations, as a generic drug discovery assay for many other GPCRs of which the activation leads to a release of intracellular Ca2+.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29553532      PMCID: PMC5931321          DOI: 10.3791/56780

Source DB:  PubMed          Journal:  J Vis Exp        ISSN: 1940-087X            Impact factor:   1.355


  35 in total

Review 1.  Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors.

Authors:  Roland Seifert; Katharina Wenzel-Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2002-09-06       Impact factor: 3.000

Review 2.  Strategies for the identification of allosteric modulators of G-protein-coupled receptors.

Authors:  Neil T Burford; John Watson; Robert Bertekap; Andrew Alt
Journal:  Biochem Pharmacol       Date:  2010-12-22       Impact factor: 5.858

3.  The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes.

Authors:  Karl Balabanian; Bernard Lagane; Simona Infantino; Ken Y C Chow; Julie Harriague; Barbara Moepps; Fernando Arenzana-Seisdedos; Marcus Thelen; Françoise Bachelerie
Journal:  J Biol Chem       Date:  2005-08-17       Impact factor: 5.157

4.  Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4.

Authors:  D Schols; J A Esté; G Henson; E De Clercq
Journal:  Antiviral Res       Date:  1997-08       Impact factor: 5.970

Review 5.  Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2011-08-20       Impact factor: 9.546

6.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints.

Authors:  Robert Fredriksson; Malin C Lagerström; Lars-Gustav Lundin; Helgi B Schiöth
Journal:  Mol Pharmacol       Date:  2003-06       Impact factor: 4.436

Review 7.  Signaling through G protein coupled receptors.

Authors:  Narendra Tuteja
Journal:  Plant Signal Behav       Date:  2009-10-14

Review 8.  The intricate role of CXCR4 in cancer.

Authors:  Samit Chatterjee; Babak Behnam Azad; Sridhar Nimmagadda
Journal:  Adv Cancer Res       Date:  2014       Impact factor: 6.242

9.  Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma.

Authors:  John F DiPersio; Ivana N Micallef; Patrick J Stiff; Brian J Bolwell; Richard T Maziarz; Eric Jacobsen; Auayporn Nademanee; John McCarty; Gary Bridger; Gary Calandra
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

10.  A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development.

Authors:  Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall
Journal:  J Exp Med       Date:  2006-08-28       Impact factor: 14.307

View more
  3 in total

1.  Stimulation of the atypical chemokine receptor 3 (ACKR3) by a small-molecule agonist attenuates fibrosis in a preclinical liver but not lung injury model.

Authors:  Tom Van Loy; Steven De Jonghe; Karolien Castermans; Wouter Dheedene; Reinout Stoop; Lars Verschuren; Matthias Versele; Patrick Chaltin; Aernout Luttun; Dominique Schols
Journal:  Cell Mol Life Sci       Date:  2022-05-13       Impact factor: 9.207

2.  Synthesis and Anti-HIV Activity of a Novel Series of Isoquinoline-Based CXCR4 Antagonists.

Authors:  Mastaneh Safarnejad Shad; Sandra Claes; Eline Goffin; Tom Van Loy; Dominique Schols; Steven De Jonghe; Wim Dehaen
Journal:  Molecules       Date:  2021-10-18       Impact factor: 4.411

3.  A Set of Experimentally Validated Decoys for the Human CC Chemokine Receptor 7 (CCR7) Obtained by Virtual Screening.

Authors:  Matic Proj; Steven De Jonghe; Tom Van Loy; Marko Jukič; Anže Meden; Luka Ciber; Črtomir Podlipnik; Uroš Grošelj; Janez Konc; Dominique Schols; Stanislav Gobec
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.